No Data
Plant Co's Profit Slides 20% in Fiscal Q1
Stocks that moved the day before part 1: Renascience, Iwai Cosmo, Hioki Electric, ETC.
Ticker Symbol <Code> Closing Price on the 27th ⇒ Change from the previous day. Mizuho Medical <4595> 1524 +932 Financial Estimates for the fiscal year ending December 2024 revised upwards. Japan Kogyo <5279> 810 +47 Operating profit for the cumulative third quarter increased by 78.1%, shifting from a significant loss in the first half to a large profit. Toho Steel <5423> 1560 +33 Performance forecast for the fiscal year ending March 2025 revised upwards. PLANT <7646> 1537 -114 Operating profit decreased by 21.5% in the first quarter. Rena Science <4889> 1.
Afternoon session [Active stocks and traded stocks]
*Mizuho Medical <4595> 1524 +9 Revised upwards the profit and Dividends estimates for the fiscal year ending December 2024. *Japan Investment <5279> 810 +47 The cumulative operating profit for the third quarter increased by 78.1%, turning from a loss in the first half to a significant gain. *Tokyo Steel <5423> 1560 +33 Upgraded the performance forecasts for the fiscal year ending March 2025. *PLANET <7646> 1537 -11 Operating profit for the first quarter decreased by 21.5%. *Renascience <4889> 1325 +28 North Su
January 27th [Today's Investment Strategy]
[Fisco Selected Stocks] 【Material Stocks】 Gendai Agency <2411> 366 yen (1/24) engaged in planning and production of advertising and publicity. The financial estimates for the fiscal year ending March 2025 have been revised upwards. Operating profit is estimated at 0.4 billion yen (a 60.6% increase compared to the previous period). This is approximately a 33% increase from the previous estimate. Although print media is declining, mainly internet advertising is performing well, and revenue is expected to remain consistent with previous estimates. Profit is benefiting from the strong sales of high-margin services and internet advertising.
Focus on Obic and Iwai Koss Corp, while Astellas Pharma and Fujicco may be struggling.
In the U.S. stock market last weekend on the 24th, the Dow Jones Industrial Average was down $140.82 at 44,424.25, the Nasdaq Composite Index was down 99.38 points at 19,954.30, and the Chicago Nikkei 225 Futures were up 540 yen compared to the Osaka daytime at 40,480 yen. The exchange rate was 1 dollar = 155.70-80 yen. Today in the Tokyo market, Iwai Kasei <8707> announced in its earnings report that the operating profit for the cumulative third quarter is expected to increase by 30.4%, and the operating profit for the cumulative third quarter is up 9.5%, with the end-of-period dividends revised from the previous financial estimates.
Astellas Pharma revised its operating profit downward for March 25 to 11 billion yen, down from 80 billion yen.
Astellas Pharma <4503> announced a revision of its financial estimates for the fiscal year ending March 2025. The operating profit has been revised downward from 80 billion yen to 11 billion yen. The net profit has been adjusted down from 50 billion yen to 14 billion yen. Due to the withdrawal of the marketing approval application for the treatment drug "Aizavei" for age-related macular degeneration, which poses a risk of blindness, a review of future plans has been conducted, leading to the recognition of an impairment loss of approximately 116 billion yen for related intangible assets as other expenses. [Positive Evaluation] <6866> HIOKI Electric.